麻豆传媒

Oncology/Hematology >

Renal Cell Carcinoma

News, opinions and meeting coverage in oncology/hematology.

Will Biomarkers Eventually Replace Physicians?

Milton Packer imagines the end of nonprocedural medicine as we know it

Kidney Stones Tied to Renal Carcinoma

But more research is needed to unravel mechanisms behind the relationships, study authors say

SABR Equally Effective in RCC Patients With One or Both Kidneys

Minimal side effects reported with high-dose treatment

Combination Slows Advanced RCC

Avelumab-axitinib beneficial, irrespective of PD-L1 status

Morning Break: Human Side of Addiction; Eyeing Da Vinci's Genius; No CV Indication for Ilaris

Health news and commentary from around the Web gathered by the 麻豆传媒 staff

Many with Metastatic Kidney Cancer Can Skip Surgery

Overall survival with single-agent sunitinib better than with resection

High Suicide Rate in Urologic Ca Patients

Four to five times higher in British study

mRCC Agents: Similar Outcomes in Cross-Trial Comparison

PFS, OS not that different between axitinib and cabozantinib

Stool Bacteria May Influence Tx Response in RCC

Also, antibiotic use just before treatment may impact disease progression

Kidney Cancer Patients Take to Twitter for Support, Info

Social media platform may be useful for trial recruitment, researchers say

Insurance Status Linked to mRCC Survival Odds

Patients with private insurance get better treatment, have better outcomes

AUA 2017: New Sessions, Encores, Variety

'Something for everybody' in urology

MSK Cancer Alliance: Mainly About Medicine

Bi-directional relationship strengthens regional cancer care

Cancer Drugs' Benefit Continues After Drug Stopped

Response for as long as 20 months after PD-1/PD-L1 stopped

Antibiotics May Damper Effect of PD-1/PD-L1 Blockade

Worse PFS in metastatic renal cell carcinoma

Slippery Slope: A Targeted Therapy That Misses the Mark?

Afinitor racks up FDA approvals, but where is the evidence?

Clinical Focus In Renal Cell Carcinoma: Clues from Gene Studies

Mutations in four genes appear to play a key role in the origin of renal cell carcinoma.

Medicare to Pay for More FDG-PET Scans

WASHINGTON -- Up to three scans using 18F-fluorodeoxyglucose-enhanced positron emission tomography technology can be covered by Medicare for oncology treatment planning, the Centers for Medicare and Medicaid Services said.